Design and synthesis of novel imidazo[1,2- a ]quinoxalines as PDE4 inhibitors
摘要:
New imidazo[1,2-a]quinoxaline derivatives have been synthesised by condensation of an appropriate alpha-aminoalcohol with a quinoxaline followed by intramolecular cyclisation and nucleophilic substitutions. Their phosphodiesterase inhibitory activities have been assessed on a preparation of the PDE4 isoform purified from a human alveolar epithelial cell line (A549). These studies showed potent inhibitory properties that emphasize the importance of a methyl amino group at position 4 and a weakly hindered group at position 1. (C) 2004 Elsevier Ltd. All rights reserved.
The present disclosure provides substituted cyclohexylamine compounds having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2a
, R
2b
, R
3a
, R
3b
, R
4
, R
5
, and R
7
are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
申请人:Bayer Corporation
公开号:US06353006B1
公开(公告)日:2002-03-05
This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.
The present invention relates to amino-substituted imidazopyridazine compounds of general formula(I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.
本申请描述了对治疗、预防和/或改善疾病有用的有机化合物。
Chiral‐Organotin‐Catalyzed Kinetic Resolution of Vicinal Amino Alcohols
作者:Hui Yang、Wen‐Hua Zheng
DOI:10.1002/anie.201909700
日期:2019.11.4
A highlyefficientkineticresolution of racemic amino alcohols has been achieved for the first time with a chiral tin catalyst. A chiral organotin compound with 3,4,5-trifluorophenyl groups at the 3,3'-positions of the binaphthyl framework enabled this transformation with excellent yield and highenantioselectivity. The process tolerates aryl- and alkyl-substituted amino alcohols and a variety of